

Terbinafine 250mg tablets
Effective 11/27/2017

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

N/A

Coverage Guidelines

The Plan will approve quantities over 30 tablets per 30 days and 84 tablets per year may be granted if the member meets the following criteria:

- The request is for a one-month continuation of treatment due to extensive toenail onychomycosis infection for a member who has received a 3-month course of therapy

Continuation of Therapy

Reauthorization will require documentation of a positive response to therapy.

Limitations

- Approvals will be granted for 1 tablet daily (#28 tablets) for 4 weeks only

References

- Lamisil® [package insert]. East Hanover, NJ; Novartis. 2013 Oct.
- Lamisil Granules® [package insert]. East Hanover, NJ; Novartis, 2013 Oct.
- Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. UpToDate. Version 15.3, 2007. Accessed on 11/5/07.
- De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250mg/day vs. itraconazole 200 mg/day. J Amer Acad Derm. 1998 May; 38(5 Pt 3):S57-63.
- Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J Am Acad Derm. 1996;34:116-21.

6. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis: Guidelines of the German Society of Dermatology. *Mycoses*. 2007;50:321-327.
7. Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. *J Drugs Dermatol*. Apr 2008;7(4):369-72.
8. Koesternblatt EK, Weinberg JM. Superficial fungal diseases of the hair, skin, and nails (Section 25). *Clinical Infectious Disease*. 2008. Page 173.
9. Tinea Capitis (Section 3). *RedBook: 2012 Report of the Committee on Infectious Diseases (29th edition)*. 2012.

Review History

11/26/07 – Updated
03/27/08 – Lamisil granules
11/24/08 – Reviewed
11/23/09 – Reviewed
11/22/10 – Reviewed
11/28/11 – Reviewed
11/26/12 – Reviewed
11/25/13 – Updated
11/24/14 – Reviewed
11/27/17 – Reviewed.

